OBJECTIVES: Gastro esophageal reflux disease (GERD) is commonly associated with a significant adverse impact on the patient's quality of life, his/her employment record, and healthcare systems. The aim of this analysis was to conduct a pooled analysis of the data from five European studies (GERD Management Project) to assess the potential benefit for healthcare providers of a structured treatment pathway (STP) for the treatment of GERD. METHODS: We conducted a meta-analysis of five cluster randomised clinical trials comparing a new management strategy with usual care in patients with GERD conducted in Austria, Italy, Norway, Spain and Sweden (NCT00842387). The educational intervention on investigators was based on the GerdQ questionnaire to stratify adult patients with classical symptoms of GERD according to the frequency and impact of symptoms. The most effective acid-suppressive therapy (esomeprazole 40 mg once daily) was proposed to be used only in patients with the highest GerdQ symptom impact score (Ն3 of a possible 6). Calculations were performed using data on mean values for resource utilization (including emergency room visits, hospitalization, primary-care physician visits, specialist visits and endoscopies) multiplied by the unit cost of each variable. UK unit costs were applied to the entire European cohort. RESULTS: 1947 patients were included in the analysis, 944 (49%) on the STP group and 1003 (51%) on the usual clinical practice (UCP) group. In the STP group, GerdQ scores improved significantly more during therapy than in the UCP group. Patients in the STP group had lower overall healthcare costs, 107.59€ per patient/year, than those in the UCP group, 137.55€ per patient/year (i.e. 22% reduction in healthcare utilization costs). CONCLUSIONS: The implementation of a structured treatment pathway for the treatment of GERD based in the GerdQ questionnaire could considerably reduce the disease healthcare utilization costs compared with the usual clinical practice.
sis of children and adolescents with ADHD on stimulant and atomoxetine. The study sample included children less than 18 years of age initiating stimulant or atomoxetine therapy between July 1, 2004 to December 31, 2005 . Patients with stimulant and atomoxetine were matched on propensity scores calculated based on baseline characteristics. The neurological adverse events included tics disorder (ICD-9-CM code-307.2x) and seizures 780.3, 780.39, 780.31) . Conditional logistic regression was used to account for the matched pair design. The final logistic model was adjusted for duration of therapy/persistency along with other covariates which were significant after matching. Sensitivity analysis was also performed using pharmacotherapy as the main outcome measure for management of neurological adverse events. RESULTS: The propensity score matched cohort consisted of a total of 7,424 children with ADHD (3,712-Atomoxetine users and 3,712-Stimulant users). Conditional logistic regression revealed that stimulant or atomoxetine use did not differ in terms of the risk of neurological adverse events development (Odds Ratio [OR]-0.86; 95% Confidence Interval [CI]-0.57-1.28). However, central nervous system pathology was significantly associated with the development of neurological adverse events (OR-2.87; 95% CI-1.19-6.92). Sensitivity analysis showed that stimulant use (OR-1.36; 95% CI-1.18-1.56) was positively associated with the treatments for neurological adverse events. CONCLUSIONS: Stimulant use was not significantly associated with diagnosis of neurological adverse events compared to atomoxetine in children. However, sensitivity analysis revealed that the stimulant users had an increased chance of receiving treatments for neurological adverse events. The findings suggest that stimulant use can lead to neurological adverse events which are not documented in ADHD patients but are usually treated. A total of 1,363(7.6%) subjects had a hospitalization for pneumonia during follow-up. The proportion of hospitalizations was similar in the atypical (7.5%) and the typical antipsychotic (8.0%) groups. A total of 2,335 propensity score-matched pairs were obtained using the Greedy 5-1 matching algorithm. In the matched cohort, there were 186 (7.97%) pneumonia hospitalizations in typical users compared to 179 (7.67%) among atypical users. Typical antipsychotics users did not differ significantly from atypical users on the risk of pneumonia (odds ratio: 1.042, 95% CI: 0.843-1.288). Sensitivity analysis using propensity score as a continuous variable in a multivariable logistic regression model yielded similar results (odds ratio: 0.976, 95% CI: 0.828-1.150). CONCLUSIONS: The risk of hospitalization for pneumonia was similar for new users of typical and atypical antipsychotic drugs. While this indicates that there is no added safety concern for users of atypical antipsychotics, it also suggests there is no added advantage of atypical use, especially in patients at high risk for pneumonia. All study subjects were followed for 180 days from index date, the date of first antipsychotic prescription. Propensity scores were calculated for each individual using pre-index demographics, comorbidities, and medication use. Users of atypical antipsychotics and typical antipsychotics were matched on propensity score using the Greedy 5-1 matching algorithm. Conditional logistic regression model stratified on propensity score-matched pair was used to compare the risk of hospitalization for hip fracture in new users of atypical versus typical antipsychotic drugs; sensitivity analysis was conducted using propensity score as a continuous, linear term in the unmatched study cohort using logistic regression. RESULTS: 15,637 new users of atypical and 2,337 new users of typical antipsychotic drugs were identified. 307 (1.7%) of all antipsychotic users had a hospitalization for hip fracture during follow-up. Of these, 40 were typical and 267 were atypical users. In the propensity score-matched cohort of 4,660 individuals (2,330 pairs), 40 (1.72%) typical antipsychotic users and 38 (1.63%) atypical antipsychotic users had a hospitalization for hip fracture during follow-up. The risk of hip fracture was not found to be statistically significant (odds ratio: 1.056; 95% CI: 0.669-1.665) between atypical and typical antipsychotic users. Similar results were obtained in sensitivity analysis (odds ratio: 1.089; 95% CI: 0.775-1.530). CONCLUSIONS: Typical and atypical antipsychotic drug use in an elderly Medicare population has similar risks of hip fracture.
PMH2

RISK OF HOSPITALIZATION FOR PNEUMONIA ASSOCIATED WITH THE USE OF ATYPICAL VERSUS TYPICAL ANTIPSYCHOTICS IN A NATIONAL SAMPLE OF MEDICARE BENEFICIARIES
PMH3
RISK OF HIP FRACTURES IN ELDERLY MEDICARE BENEFICIARIES USING ATYPICAL OR TYPICAL ANTIPSYCHOTICS: A PROPENSITY SCORE ANALYSIS
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RISK OF FALLS AND FRACTURES IN OLDER ADULTS USING ATYPICAL ANTIPSYCHOTICS-A MULTIPLE PROPENSTY SCORE ADJUSTED RETROSPECTIVE COHORT STUDY
Chatterjee S, Chen H, Johnson ML, Aparasu RR University of Houston, Houston, TX, USA OBJECTIVES: The study evaluated the risk of falls and fractures associated with use of risperidone, olanzapine and quetiapine among community-dwelling older adults in the US. METHODS: The study involved a multiple propensity score-adjusted retrospective cohort design and included older adults aged 50 years and above, who initiated prescriptions of risperidone, olanzapine or quetiapine between July 1, 2000 and June 30, 2008 using IMS LifeLink Health Plans Claims database. Patients were followed until hospitalization/emergency room (ER) visit for accidental fall/hip fracture, or the end of the study period, whichever occurred earlier. Propensity score-adjusted Cox proportional hazard regression model was used to evaluate the relative risk of falls or fractures. The covariates in the final model included maximum dose of antipsychotic therapy, and exposure to other psychotropic medications that increase the risk of falls or fractures. RESULTS: There were 12,145 (5,083 risperidone, 4,377 olanzapine and 2,685 quetiapine) new users of atypical agents. A total of 380 cases of falls or fractures with at least one hospitalization/ ER visit following the use of antipsychotic agents were identified. The number of falls or fractures for risperidone, olanzapine and quetiapine were 165 (3.65%), 109 (2.81%) and 106 (4.47%) respectively. After adjusting for propensity scores and other covariates, the Cox proportional hazard model showed that there was no statistically significant difference with use of risperidone (hazard ratio, HR-1.11; 95% CI-0.85-1.45) or quetiapine (HR-1.16; CI-0.87-1.53) compared to olanzapine in the risk of falls or fractures. CONCLUSIONS: The study found no significant difference across the individual atypical agents in the risk of falls or fractures in a large cohort of older adults. Future studies are required to evaluate the overall safety profiles of atypical antipsychotics in the above population. OBJECTIVES: Attention deficit hyperactivity disorder (ADHD) is a common psychiatric disorder of childhood, and the methylphenidate hydrochloride (MPH) is the most frequently and well-established prescribed pharmacotherapy for ADHD. Warnings by the United States Food and Drug Administration on psychiatric adverse effects have concerns for drug safety. Existing studies to date demonstrate that MPH's safety of children with ADHD which get inconsistent results. The purpose was to evaluate the potential association between MPH treatment and the subsequent development of psychiatric disorders such as disruptive, anxiety, mood, learning, tic and substance-related disorders. METHODS: A retrospective cohort study was conducted. Study subjects selected were aged 6 to 18 years on the date of the first diagnosed for ADHD between 2001 and 2006. Patients were divided into 2 groups: ever-using MPH and not-using MPH. The authors conducted casecontrol matching on the propensity score to reduce selection bias. The Cox Proportional Hazards Model was used to assess the association of use of MPH with the subsequent risks of psychiatric events occurring. RESULTS: The results shows that the MPH group had a significantly higher hazard ratio (HR) of patients diagnosed with oppositional defiant disorder (ODD) (HR ϭ 1.807, P Ͻ 0.001), conduct disorder (CD) (HR ϭ 1.225, P ϭ 0.0460), and anxiety disorders (AD) (HR ϭ 1.921, P Ͻ 0.001). The MPH group had a significantly lower HR of patients diagnosed with learning disorders (LD) (HR ϭ 0.818, P ϭ 0.0029). In addition, the authors found the MPH group had a significantly higher HRs of ODD and CD and a significantly lower HR of LD in boys only. CONCLUSIONS: Our study found that MPH treatment is associated with a higher risk of development of oppositional defiant disorder, conduct disorder and anxiety disorders and a lower risk of learning disorders.
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PMH6 DIFFERENTIAL RATES OF SIDE EFFECTS IN DEPRESSED ADULTS AND ADOLESCENTS BEING TREATED WITH ANTIDEPRESSANTS
Anderson HD, Libby AM, Pace WD, West DR, Valuck RJ University of Colorado, Denver, Aurora, CO, USA OBJECTIVES: Antidepressants are first line treatment for depression. Effectiveness may be compromised because of discontinuation, which is commonly associated with side effects. Using a national database of medical and pharmacy claims, we sought to identify and compare the prevalence of side effects in newly depressed adult and adolescent patients taking different classes of antidepressants.
METHODS:
A new-user design was implemented using 11 years of data to identify a retrospective cohort of newly depressed subjects on antidepressant monotherapy, defined as SSRI, SNRI, TCA, MAOI, buproprion, phenylpiperazine, or tetracyclic. Rates of side effects (per 1,000 person-months of exposure) were calculated within each antidepressant group; relative risks were calculated (SSRI as referent group). Propensity-adjusted Cox Proportional Hazards regression was used to model the likelhood of side effects adjusted for demographic, clinical and treatment characteristics. RESULTS: A total of 40,017 patients had a new episode of depression and were on antidepressant monotherapy within 30 days of diagnosis [SSRI (66%), Bupropion (14%), SNRI (12%), other (8%)]. The most common side effects were headache (up to 16.8 per 1,000 person-months of therapy in adults, 17.6 per 1,000 in adolescents) and nausea (up to 7.2 per 1,000 in adults, 9.3 per 1,000 in adolescents). Relative to adults receiving SSRIs, those receiving SNRIs had higher risk of nausea (HRϭ1.28, 95%CIϭ1.08-1.52), and of having one or more side effect of any type (HRϭ1.23, 95%CIϭ1.10-1.37). Adults taking bupropion were less likely to have sedation (HRϭ0.36, . Adolescent receiving an SNRI were more likely to experience sedation compared to adolescents receiving an SSRI (HRϭ3.14, . CONCLUSIONS: Side effects detected in claims must be significant enough to be reported to the provider and medically coded, so these rates are underestimates. Nevertheless, the reported rates are nontrivial. Future work will account for side effects in the likelihood of discontinuation and associated reduced comparative effectiveness. OBJECTIVES: Selective Serotonin Reuptake Inhibitors (SSRIs) are widely used antidepressants. Pharmacokinetic and pharmacodynamic differences among the SS-RIs can give rise to differences in drug-drug interaction (DDI) potential. This study estimated the effect of initial SSRI choice on the likelihood of receiving a potentially interacting drug (and thus a potential SSRI-DDI) among subjects initiating therapy with SSRIs in the United States managed health care plans. METHODS: Using a large health insurance claims database (IMS LifeLink Database), we examined retrospective cohorts of new SSRI users between 2002-2008. For each new SSRI user, we used medical and pharmacy claims to identify instances and crude rates of potential SSRI-DDI according to compendia and expert panel based lists of interactions. We calculated crude and adjusted incidence rate ratios for potential SSRI-DDI based on the initial SSRI prescribed, adjusting for demographic, clinical, and prescriber related factors, length of SSRI exposure and propensity for receiving escitalopram as the initial SSRI using Poisson regression methods. RESULTS: A total of 913,619 subjects met inclusion criteria. Using the compendia list of SSRI-DDI, 48.5-62.0% of subjects had at least one instance of coprescribing of potentially interacting drug(s) with SSRI. Compared to escitalopram users, citalopram (HR [Hazard Ratio]ϭ1.05, pϽ0.01), fluoxetine (HRϭ1.03, pϽ0.01), fluvoxamine (HRϭ1.17, pϽ0.01), and paroxetine (HRϭ1.05, pϽ0.01) users all demonstrated a higher likelihood of potential SSRI-DDI. Sertraline (HRϭ0.99, pϭ0.32) users demonstrated a similar likelihood of potential SSRI-DDI as escitalopram. Results were similar for the expert panel list of SSRI-DDI. CONCLUSIONS: SSRIs are widely used, and coprescribing of drugs with the potential to elicit SSRI-DDI may be more frequent than is often reported. Among SSRIs, escitalopram and sertraline are associated with a lower likelihood of being co-prescribed with a potentially interacting drug. Clinicians, pharmacists and patients should be aware of the potential for such interactions, and further study is needed to identify subsequent patient outcomes.
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LIKELIHOOD OF POTENTIAL DRUG-DRUG INTERACTIONS AMONG PERSONS INITIATING THERAPY WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS: EFFECT OF INITIAL SSRI AND OTHER FACTORS
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EFFECT OF VARIOUS ANTIDEPRESSANT GROUPS ON BONE MINERAL DENSITY (BMD)
